Literature DB >> 22357867

Isoform-specific toxicity of Mecp2 in postmitotic neurons: suppression of neurotoxicity by FoxG1.

Somasish Ghosh Dastidar1, Farah H Bardai, Chi Ma, Valerie Price, Varun Rawat, Pragya Verma, Vinodh Narayanan, Santosh R D'Mello.   

Abstract

The methyl-CpG binding protein 2 (MeCP2) is a widely expressed protein, the mutations of which cause Rett syndrome. The level of MeCP2 is highest in the brain where it is expressed selectively in mature neurons. Its functions in postmitotic neurons are not known. The MeCP2 gene is alternatively spliced to generate two proteins with different N termini, designated as MeCP2-e1 and MeCP2-e2. The physiological significance of these two isoforms has not been elucidated, and it is generally assumed they are functionally equivalent. We report that in cultured cerebellar granule neurons induced to die by low potassium treatment and in Aβ-treated cortical neurons, Mecp2-e2 expression is upregulated whereas expression of the Mecp2-e1 isoform is downregulated. Knockdown of Mecp2-e2 protects neurons from death, whereas knockdown of the e1 isoform has no effect. Forced expression of MeCP2-e2, but not MeCP2-e1, promotes apoptosis in otherwise healthy neurons. We find that MeCP2-e2 interacts with the forkhead protein FoxG1, mutations of which also cause Rett syndrome. FoxG1 has been shown to promote neuronal survival and its downregulation leads to neuronal death. We find that elevated FoxG1 expression inhibits MeCP2-e2 neurotoxicity. MeCP2-e2 neurotoxicity is also inhibited by IGF-1, which prevents the neuronal death-associated downregulation of FoxG1 expression, and by Akt, the activation of which is necessary for FoxG1-mediated neuroprotection. Finally, MeCP2-e2 neurotoxicity is enhanced if FoxG1 expression is suppressed or in neurons cultured from FoxG1-haplodeficient mice. Our results indicate that Mecp2-e2 promotes neuronal death and that this activity is normally inhibited by FoxG1. Reduced FoxG1 expression frees MecP2-e2 to promote neuronal death.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22357867      PMCID: PMC3403752          DOI: 10.1523/JNEUROSCI.5841-11.2012

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  45 in total

1.  The expression of methyl CpG binding factor MeCP2 correlates with cellular differentiation in the developing rat brain and in cultured cells.

Authors:  Benjamin P Jung; Denis G M Jugloff; Guangming Zhang; Richard Logan; Stephanie Brown; James H Eubanks
Journal:  J Neurobiol       Date:  2003-04

2.  Targeting of cre to the Foxg1 (BF-1) locus mediates loxP recombination in the telencephalon and other developing head structures.

Authors:  J M Hébert; S K McConnell
Journal:  Dev Biol       Date:  2000-06-15       Impact factor: 3.582

3.  Foxg1 suppresses early cortical cell fate.

Authors:  Carina Hanashima; Suzanne C Li; Lijian Shen; Eseng Lai; Gord Fishell
Journal:  Science       Date:  2004-01-02       Impact factor: 47.728

4.  Telencephalon-restricted expression of BF-1, a new member of the HNF-3/fork head gene family, in the developing rat brain.

Authors:  W Tao; E Lai
Journal:  Neuron       Date:  1992-05       Impact factor: 17.173

5.  Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.

Authors:  Robert J Ferrante; James K Kubilus; Junghee Lee; Hoon Ryu; Ayshe Beesen; Birgit Zucker; Karen Smith; Neil W Kowall; Rajiv R Ratan; Ruth Luthi-Carter; Steven M Hersch
Journal:  J Neurosci       Date:  2003-10-15       Impact factor: 6.167

6.  Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice.

Authors:  Sandra Luikenhuis; Emanuela Giacometti; Caroline F Beard; Rudolf Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-06       Impact factor: 11.205

7.  Brain factor-1 controls the proliferation and differentiation of neocortical progenitor cells through independent mechanisms.

Authors:  Carina Hanashima; Lijian Shen; Suzanne C Li; Eseng Lai
Journal:  J Neurosci       Date:  2002-08-01       Impact factor: 6.167

8.  The major form of MeCP2 has a novel N-terminus generated by alternative splicing.

Authors:  Skirmantas Kriaucionis; Adrian Bird
Journal:  Nucleic Acids Res       Date:  2004-03-19       Impact factor: 16.971

9.  A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome.

Authors:  Gevork N Mnatzakanian; Hannes Lohi; Iulia Munteanu; Simon E Alfred; Takahiro Yamada; Patrick J M MacLeod; Julie R Jones; Stephen W Scherer; N Carolyn Schanen; Michael J Friez; John B Vincent; Berge A Minassian
Journal:  Nat Genet       Date:  2004-03-21       Impact factor: 38.330

10.  Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease.

Authors:  Emma Hockly; Victoria M Richon; Benjamin Woodman; Donna L Smith; Xianbo Zhou; Eddie Rosa; Kirupa Sathasivam; Shabnam Ghazi-Noori; Amarbirpal Mahal; Philip A S Lowden; Joan S Steffan; J Lawrence Marsh; Leslie M Thompson; Cathryn M Lewis; Paul A Marks; Gillian P Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-07       Impact factor: 11.205

View more
  35 in total

Review 1.  Epigenetics, autism spectrum, and neurodevelopmental disorders.

Authors:  Sampathkumar Rangasamy; Santosh R D'Mello; Vinodh Narayanan
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 2.  Rett syndrome and MeCP2.

Authors:  Vichithra R B Liyanage; Mojgan Rastegar
Journal:  Neuromolecular Med       Date:  2014-03-11       Impact factor: 3.843

Review 3.  Neuron-specific alternative splicing of transcriptional machineries: Implications for neurodevelopmental disorders.

Authors:  Robert S Porter; Farris Jaamour; Shigeki Iwase
Journal:  Mol Cell Neurosci       Date:  2017-12-15       Impact factor: 4.314

Review 4.  A review of Rett syndrome (RTT) with induced pluripotent stem cells.

Authors:  Vellingiri Balachandar; Venkatesan Dhivya; Mohan Gomathi; Subramaniam Mohanadevi; Balasubramanian Venkatesh; Bharathi Geetha
Journal:  Stem Cell Investig       Date:  2016-09-28

5.  Insights into the cellular and molecular contributions of MeCP2 overexpression to disease pathophysiology.

Authors:  M Morgan Taylor; Shachee Doshi
Journal:  J Neurosci       Date:  2012-07-11       Impact factor: 6.167

6.  Dexamethasone induces a putative repressor complex and chromatin modifications in the CRH promoter.

Authors:  Dharmendra Sharma; Shreyas Bhave; Elaine Gregg; Rosalie Uht
Journal:  Mol Endocrinol       Date:  2013-05-13

7.  14q12 microdeletions excluding FOXG1 give rise to a congenital variant Rett syndrome-like phenotype.

Authors:  Carolyn J Ellaway; Gladys Ho; Elisa Bettella; Alisa Knapman; Felicity Collins; Anna Hackett; Fiona McKenzie; Artur Darmanian; Gregory B Peters; Kerry Fagan; John Christodoulou
Journal:  Eur J Hum Genet       Date:  2012-09-12       Impact factor: 4.246

Review 8.  MeCP2: multifaceted roles in gene regulation and neural development.

Authors:  Tian-Lin Cheng; Zilong Qiu
Journal:  Neurosci Bull       Date:  2014-08-01       Impact factor: 5.203

9.  A New Approach to Rare Diseases of Children: The Undiagnosed Diseases Network.

Authors:  Chloe M Reuter; Elise Brimble; Colette DeFilippo; Annika M Dries; Gregory M Enns; Euan A Ashley; Jonathan A Bernstein; Paul Graham Fisher; Matthew T Wheeler
Journal:  J Pediatr       Date:  2018-01-11       Impact factor: 4.406

10.  Platelet defects in congenital variant of Rett syndrome patients with FOXG1 mutations or reduced expression due to a position effect at 14q12.

Authors:  Christophe Goubau; Koen Devriendt; Nathalie Van der Aa; An Crepel; Dagmar Wieczorek; Tjitske Kleefstra; Marjolein H Willemsen; Anita Rauch; Andreas Tzschach; Thomy de Ravel; Peter Leemans; Chris Van Geet; Gunnar Buyse; Kathleen Freson
Journal:  Eur J Hum Genet       Date:  2013-05-01       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.